The current advanced pipeline includes Androgen Restored Contraception (ARC), Estetrol (E4) and Zona Pellucida (ZP) immunotherapy (antigen immunisation). ZP (active immunisation) for ovarian cancer has been sold to HRA Pharma (France) in October 2014, whereas the other applications (including passive immunisation for ovarian cancer) were retained by PRB. All rights on E4 have been sold to Mithra Pharmaceuticals (Belgium) in March 2015, whereas PRB has exclusively licensed back the rights on oncological and veterinary applications. The ARC pill is licensed out to Gedeon Richter (Hungary) in January 2019 for the regions Europe, Russia, Latin America and Australia.
PRB has founded a subsidiary company – Pantarhei Oncology (PRO) – to develop oncological treatments with a current focus on breast and prostate cancer.